Puma Biotechnology (NASDAQ:PBYI) Director Adrian Senderowicz Sells 27,000 Shares of Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Adrian Senderowicz sold 27,000 shares of the stock in a transaction on Friday, June 12th. The stock was sold at an average price of $7.20, for a total value of $194,400.00. Following the completion of the transaction, the director owned 27,000 shares of the company’s stock, valued at $194,400. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Puma Biotechnology Stock Performance

NASDAQ:PBYI opened at $7.07 on Tuesday. The stock has a fifty day moving average price of $7.23 and a two-hundred day moving average price of $6.57. The stock has a market capitalization of $359.86 million, a price-to-earnings ratio of 14.73 and a beta of 1.21. Puma Biotechnology, Inc. has a 1 year low of $3.03 and a 1 year high of $7.90.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.09. The firm had revenue of $44.81 million during the quarter, compared to analysts’ expectations of $42.00 million. Puma Biotechnology had a return on equity of 20.30% and a net margin of 10.69%. On average, analysts predict that Puma Biotechnology, Inc. will post 0.28 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on PBYI shares. Wall Street Zen lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings lowered Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold”.

Institutional Trading of Puma Biotechnology

A number of large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its stake in shares of Puma Biotechnology by 7.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,436,106 shares of the biopharmaceutical company’s stock valued at $9,175,000 after acquiring an additional 96,503 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its stake in shares of Puma Biotechnology by 35.3% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company’s stock valued at $6,666,000 after acquiring an additional 292,108 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Puma Biotechnology by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 994,345 shares of the biopharmaceutical company’s stock valued at $5,917,000 after acquiring an additional 10,823 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Puma Biotechnology by 4,823,365.0% during the third quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock valued at $5,123,000 after acquiring an additional 964,673 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Puma Biotechnology by 17.2% during the fourth quarter. State Street Corp now owns 877,077 shares of the biopharmaceutical company’s stock valued at $5,219,000 after acquiring an additional 128,419 shares during the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.